Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q13868

UPID:
EXOS2_HUMAN

ALTERNATIVE NAMES:
Exosome component 2; Ribosomal RNA-processing protein 4

ALTERNATIVE UPACC:
Q13868; A3KFL3; A3KFL4; B4DKK6; Q9NUY4

BACKGROUND:
The Exosome complex component RRP4, known alternatively as Exosome component 2 and Ribosomal RNA-processing protein 4, is integral to the RNA exosome complex. It participates in a wide range of RNA processing and degradation events, playing a key role in maintaining RNA integrity within the cell by targeting defective mRNAs and non-coding transcripts for degradation.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in RNA processing and its association with a specific genetic disorder, Exosome complex component RRP4 presents a promising target for drug discovery. Understanding the role of Exosome complex component RRP4 could open doors to potential therapeutic strategies, offering hope for treatments targeting the underlying genetic causes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.